FDA rejects Amgen’s BLA for osteoporosis treatment Evenity

By PBR Staff Writer

The US Food and Drug Administration (FDA) has rejected Amgen and UCB’s biologics license application (BLA) for Evenity (romosozumab) to treat postmenopausal women with osteoporosis